Results 111 to 120 of about 7,268 (227)

Synthesis of Amino Acids Bearing Halodifluoromethyl Moieties and Their Application to p53-Derived Peptides Binding to Mdm2/Mdm4

Drug Design, Development and Therapy, 2023
Sebastian Vaas,1 Markus O Zimmermann,1 Theresa Klett,1 Frank M Boeckler1,2 1Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Laboratory for Molecular Design and Pharmaceutical Biophysics, Institute of Pharmaceutical Sciences,
Vaas S, Zimmermann MO, Klett T, Boeckler FM   +3 more
doaj  

p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX

Biomolecules, 2019
The disordered p53 transactivation domain (p53TAD) contains specific levels of transient helical secondary structure that are necessary for its binding to the negative regulators, mouse double minute 2 (Mdm2) and MdmX.
Robin Levy, Emily Gregory, Wade Borcherds, Gary Daughdrill   +3 more
doaj   +1 more source

miR-34c-5p inhibited fibroblast proliferation, differentiation and epithelial-mesenchymal transition in benign airway stenosis via MDMX/p53 pathway

Functional & Integrative Genomics
Benign airway stenosis (BAS) means airway stenosis or obstruction that results from a variety of non-malignant factors, including tuberculosis, trauma, benign tumors, etc. In consideration of the currently limited research on microRNAs in BAS, this study
Jinmei Wei, Yan Chen, Tingmei Feng, Yu Wei, Caizhen Yang, Changwen Zhang, Wen-Tao Li, Guang-Nan Liu   +7 more
semanticscholar   +1 more source

Unleashing the Antiviral Potential of Stapled Peptides: A New Frontier in Combating Human Neurotropic Viral Infections

Microbial Biotechnology, Volume 18, Issue 9, September 2025.
Human neurotropic viruses like SARS‐CoV‐2, HSV, HOPV and RSV pose significant risks due to their ability to invade and persist in the nervous system. Stapled peptides represent a promising therapeutic approach with enhanced stability, target affinity and bioavailability, emerging as an effective strategy for neutralising human neurotropic viruses ...
Sanskruti Patil, Rakesh Rahangdale, Mukesh Pasupuleti, Puttur Santhoshkumar, Raghu Chandrashekar Hariharapura   +4 more
wiley   +1 more source

A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN

bioRxiv
The influence of the metastasis promoting proteins mutant p53 (mtp53) and MDM2 on Cancer Persistent Repair (CPR) to promote cancer cell survival is understudied.
V. Ellison, A. Polotskaia, G. Xiao, Pam Leybengrub, Wei-Gang Qiu, Rusia Lee, Ronald C. Hendrickson, Wen-Wei Hu, J. Bargonetti   +8 more
semanticscholar   +1 more source

Targeting Ubiquitin‐Specific Protease 7 with Novel 5‐Amino‐Pyrazole Inhibitors: Design, Synthesis, and Biological Evaluation

ChemMedChem, Volume 20, Issue 16, August 16, 2025.
Ubiquitin‐specific protease 7 (USP‐7) is a novel target for anticancer therapy. To further extend the structure–activity relationships of the previously USP‐7 inhibitor STIRUR‐41, a library of 5‐aminopyrazoles is reported. 1d shows a potency comparable to lead compound STIRUR‐41 and promising in silico and in vitro pharmacokinetic properties ...
Matteo Lusardi, Elva Morretta, Andrea Spallarossa, Maria Chiara Monti, Camillo Rosano, Erika Iervasi, Marco Ponassi, Matteo Mori, Fiorella Meneghetti, Chiara Brullo   +9 more
wiley   +1 more source

Proteomic studies of VEGFR2 in human placentas reveal protein associations with preeclampsia, diabetes, gravidity, and labor

Cell Communication and Signaling
VEGFR2 (Vascular endothelial growth factor receptor 2) is a central regulator of placental angiogenesis. The study of the VEGFR2 proteome of chorionic villi at term revealed its partners MDMX (Double minute 4 protein) and PICALM (Phosphatidylinositol ...
Shannon J. Ho, Dale Chaput, Rachel G. Sinkey, Amanda H. Garces, Erika P. New, Maja Okuka, Peng Sang, Sefa Arlier, Nihan Semerci, Thora S. Steffensen, Thomas J. Rutherford, Angel E. Alsina, Jianfeng Cai, Matthew L. Anderson, Ronald R. Magness, Vladimir N. Uversky, Derek A. T. Cummings, John C. M. Tsibris   +17 more
doaj   +1 more source

Clinical overview of MDM2/X targeted therapies

Frontiers in Oncology, 2016
MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions, maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation, and inhibiting its transcriptional activity.
Andrew eBurgess, Andrew eBurgess, Kee Ming Chia, Sue eHaupt, David eThomas, David eThomas, Ygal eHaupt, Elgene eLim, Elgene eLim   +8 more
doaj   +1 more source

p53 binds the mdmx mRNA and controls its translation

, 2017
MDMX and MDM2 are two nonredundant essential regulators of p53 tumor suppressor activity. MDM2 controls p53 expression levels, whereas MDMX is predominantly a negative regulator of p53 trans-activity.
Vojtesek, B., Olivares-Illana, V., Fåhraeus, Robin,, Lopez, I., Naski, N., Karakostis, K., Tournillon, A-S, Nylander, Karin,, Malbert-Colas, L., Findakly, S.   +9 more
core   +1 more source

Structural Adaptation of Secondary p53 Binding Sites on MDM2 and MDMX

Journal of Molecular Biology
The thermodynamics of secondary p53 binding sites on MDM2 and MDMX were evaluated using p53 peptides containing residues 16–29, 17–35, and 1–73. All the peptides had large, negative heat capacity (ΔCp), consistent with the burial of p53 residues F19, W23,
Pirada Serena Higbee, Guy W. Dayhoff, A. Anbanandam, Sameer Varma, G. Daughdrill   +4 more
semanticscholar   +1 more source